Literature DB >> 23982970

Pathogenesis of graft-versus-host disease: innate immunity amplifying acute alloimmune responses.

Yoshinobu Maeda1.   

Abstract

In addition to reduced-intensity conditioning, which has expanded the eligibility for hematopoietic cell transplantation (HCT) to older patients, increased availability of alternative donors, including HLA-mismatched unrelated donors, has increased access to allogeneic HCT for more patients. However, acute graft-versus-host disease (GVHD) remains a lethal complication, even in HLA-matched donor-recipient pairs. The pathophysiology of GVHD depends on aspects of adaptive immunity and interactions between donor T-cells and host dendritic cells (DCs). Recent work has revealed that the role of other immune cells and endothelial cells and components of the innate immune response are also important. Tissue damage caused by the conditioning regimen leads to the release of exogenous and endogenous "danger signals". Exogenous danger signals called pathogen-associated molecular patterns and endogenous noninfectious molecules known as damage-associated molecular patterns (DAMPs) are responsible for initiating or amplifying acute GVHD by enhancing DC maturation and alloreactive T-cell responses. A significant association of innate immune receptor polymorphisms with outcomes, including GVHD severity, was observed in patients receiving allogeneic HCT. Understanding of the role of innate immunity in acute GVHD might offer new therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23982970     DOI: 10.1007/s12185-013-1421-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  52 in total

1.  Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation.

Authors:  Ahmet H Elmaagacli; Michael Koldehoff; Heidrun Hindahl; Nina K Steckel; Rudolf Trenschel; Rudolf Peceny; Hellmut Ottinger; Peter-Michael Rath; Rudolf Stefan Ross; Michael Roggendorf; Hans Grosse-Wilde; Dietrich W Beelen
Journal:  Transplantation       Date:  2006-01-27       Impact factor: 4.939

2.  Successful treatment of refractory acute GVHD complicated by severe intestinal transplant-associated thrombotic microangiopathy using recombinant thrombomodulin.

Authors:  Yasuyuki Inoue; Shigeki Kosugi; Ikuo Miura; Yoshihiro Hatta; Jin Takeuchi
Journal:  Thromb Res       Date:  2011-01-22       Impact factor: 3.944

3.  Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination.

Authors:  Ernst Holler; Gerhard Rogler; Julia Brenmoehl; Joachim Hahn; Hans Herfarth; Hildegard Greinix; Anne M Dickinson; Gerard Socié; Daniel Wolff; Gottfried Fischer; Graham Jackson; Vanderson Rocha; Beate Steiner; Guenther Eissner; Jeorg Marienhagen; Juergen Schoelmerich; Reinhard Andreesen
Journal:  Blood       Date:  2006-01-19       Impact factor: 22.113

4.  Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R.

Authors:  Konrad Wilhelm; Jayanthi Ganesan; Tobias Müller; Christoph Dürr; Melanie Grimm; Andreas Beilhack; Christine D Krempl; Stephan Sorichter; Ulrike V Gerlach; Eva Jüttner; Alf Zerweck; Frank Gärtner; Patrizia Pellegatti; Francesco Di Virgilio; Davide Ferrari; Neeraja Kambham; Paul Fisch; Jürgen Finke; Marco Idzko; Robert Zeiser
Journal:  Nat Med       Date:  2010-11-21       Impact factor: 53.440

5.  CD44-hyaluronic acid interactions mediate shear-resistant binding of lymphocytes to dermal endothelium in acute cutaneous GVHD.

Authors:  Mirjana Milinkovic; Joseph H Antin; Charles A Hergrueter; Charles B Underhill; Robert Sackstein
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

6.  Divergence of quaternary structures among bacterial flagellar filaments.

Authors:  Vitold E Galkin; Xiong Yu; Jakub Bielnicki; John Heuser; Cheryl P Ewing; Patricia Guerry; Edward H Egelman
Journal:  Science       Date:  2008-04-18       Impact factor: 47.728

7.  Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality.

Authors:  Lisa K Jasperson; Christoph Bucher; Angela Panoskaltsis-Mortari; Andrew L Mellor; David H Munn; Bruce R Blazar
Journal:  Blood       Date:  2009-10-14       Impact factor: 22.113

8.  Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease.

Authors:  K R Cooke; G R Hill; J M Crawford; D Bungard; Y S Brinson; J Delmonte; J L Ferrara
Journal:  J Clin Invest       Date:  1998-11-15       Impact factor: 14.808

9.  Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis.

Authors:  Tomohiro Watanabe; Naoki Asano; Peter J Murray; Keiko Ozato; Prafullakumar Tailor; Ivan J Fuss; Atsushi Kitani; Warren Strober
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

10.  Improved outcome of hematopoietic SCT in patients with homozygous gene variant of Toll-like receptor 9.

Authors:  A H Elmaagacli; M Koldehoff; D W Beelen
Journal:  Bone Marrow Transplant       Date:  2009-03-02       Impact factor: 5.483

View more
  20 in total

Review 1.  Microbiome-intestine cross talk during acute graft-versus-host disease.

Authors:  Hind Rafei; Robert R Jenq
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

2.  Guest editorial: new basic and clinical aspects of graft-versus-host disease: what can we do without ‘‘Doc’’ Brown’s help?

Authors:  Akiyoshi Takami
Journal:  Int J Hematol       Date:  2013-09       Impact factor: 2.490

Review 3.  Innate immunity for better or worse govern the allograft response.

Authors:  Leo E Otterbein; Zhigang Fan; Maria Koulmanda; Thomas Thronley; Terry B Strom
Journal:  Curr Opin Organ Transplant       Date:  2015-02       Impact factor: 2.640

Review 4.  Intestinal microbiota-related effects on graft-versus-host disease.

Authors:  Yusuke Shono; Melissa D Docampo; Jonathan U Peled; Suelen M Perobelli; Robert R Jenq
Journal:  Int J Hematol       Date:  2015-03-27       Impact factor: 2.490

Review 5.  Potential of glycosylation research in graft versus host disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Ema Prenc; Drazen Pulanic; Maja Pucic-Bakovic; Marija Pezer; Lana Desnica; Radovan Vrhovac; Damir Nemet; Steven Z Pavletic
Journal:  Biochim Biophys Acta       Date:  2016-02-26

6.  Host MyD88 signaling protects against acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  S Xing; X Zhang; J H Liu; X Huang; P Zhou
Journal:  Clin Exp Immunol       Date:  2018-10-14       Impact factor: 4.330

7.  Curative haploidentical BMT in a murine model of X-linked chronic granulomatous disease.

Authors:  Yasuo Takeuchi; Emiko Takeuchi; Takashi Ishida; Masafumi Onodera; Hiromitsu Nakauchi; Makoto Otsu
Journal:  Int J Hematol       Date:  2015-04-29       Impact factor: 2.490

Review 8.  Prophylactic and therapeutic treatment of graft-versus-host disease in Japan.

Authors:  Makoto Murata
Journal:  Int J Hematol       Date:  2015-04-12       Impact factor: 2.490

9.  The Free Radical Scavenger NecroX-7 Attenuates Acute Graft-versus-Host Disease via Reciprocal Regulation of Th1/Regulatory T Cells and Inhibition of HMGB1 Release.

Authors:  Keon-Il Im; Nayoun Kim; Jung-Yeon Lim; Young-Sun Nam; Eun-Sol Lee; Eun-Jung Kim; Hyoung Jin Kim; Soon Ha Kim; Seok-Goo Cho
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

10.  A donor thrombomodulin gene variation predicts graft-versus-host disease development and mortality after bone marrow transplantation.

Authors:  Haruka Nomoto; Akiyoshi Takami; J Luis Espinoza; Keitaro Matsuo; Shohei Mizuno; Makoto Onizuka; Koichi Kashiwase; Yasuo Morishima; Takahiro Fukuda; Yoshihisa Kodera; Noriko Doki; Koichi Miyamura; Takehiko Mori; Shinji Nakao; Shigeki Ohtake; Eriko Morishita
Journal:  Int J Hematol       Date:  2015-08-06       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.